EMA Authorised: Foscan (temoporfin) — Biolitec Pharma Ltd

View source ↗

Summary

The European Medicines Agency authorised Foscan (temoporfin) for head and neck squamous cell carcinoma, with Biolitec Pharma Ltd as the marketing authorization …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Foscan (temoporfin)

Snippet

Status: Authorised. Therapeutic area: Head and Neck Neoplasms;Carcinoma, Squamous Cell. MAH: Biolitec Pharma Ltd. Decision date: 29/03/2016